drugset / Trial / NCT03220399
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2
Timeline
- Start
- 2019-12-01
- Primary completion
- 2020-03-28
- Completion
- 2020-07-31
Outcome
Outcome not reported
Stopped: “Decided to stop drug development”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NVP-1603-1 | Unknown | — | Oral |
| Subject | NVP-1603-2 | Unknown | — | Oral |
Indications
No indication recorded.